Concrete examples of biased agonism that have clearly improved therapeutic outcomes include the development of -arrestinbiased angiotensin II receptor ligands (which showed reduced hypertension-related adverse effects in preclinical models) and carfentanil-class opioid analogs designed to preferentially engage G-protein over arrestin pathways, thereby reducing respiratory depression (Schmid et al., 2017)
The FDA issued safety warnings about compounded BPC-157 products in 2024
Bandeira SDM, Da Fonseca LJS, Guedes GDS, Rabelo LA, Goulart MO, Vasconcelos SML
This requirement ensures that the treatment is appropriate for the individual's specific health needs and that it's administered safely
Some experts and Kennedy argue that offering peptides through licensed compounding pharmacies would shrink this underground market and direct people toward safer products
76 LiDYSmithDGHardelandRYangMYXuHLZhangLet al